Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

Szu-Yuan Wu, Wan-Ming Chen, Yi-Chan Chen, Ming-Feng Chiang, Ming-Che Lee, Ruey-Shyang Soong

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

METHODS: The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association.

RESULTS: After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively).

CONCLUSION: AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.

Original languageEnglish
Pages (from-to)101393
JournalDiabetes and Metabolism
Volume49
Issue number1
DOIs
Publication statusE-pub ahead of print - Sep 2022

Fingerprint

Dive into the research topics of 'Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this